NVO
What one share of Novo Nordisk A/S holds
Pharmaceutical Preparations
Novo Nordisk is a global healthcare company and a world leader in Obesity and Diabetes care. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Novo Nordisk A/S’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $10.53 |
|---|---|
| Profit | $3.49 |
| Capex (buildings and equipment) | $2.05 |
| Free cash flow | $2.01 |
| Dividends | $1.76 |
| Cash and investments | $0.94 |
| Debt | $4.63 |
| Book value | $6.86 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $3.85 | $1.23 | $0.28 | $1.19 | — | $1.80 |
| 2020 | $4.15 | $1.38 | $0.19 | $1.51 | — | $2.21 |
| 2021 | $4.86 | $1.65 | $0.22 | $1.68 | — | $2.33 |
| 2022 | $5.51 | $1.73 | $0.38 | $2.08 | — | $2.67 |
| 2023 | $7.50 | $2.70 | $0.83 | $2.68 | — | $3.55 |
| 2024 | $9.44 | $3.28 | $1.53 | $2.40 | — | $4.48 |
| 2025 | $10.53 | $3.49 | $2.05 | $2.01 | — | $6.86 |